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Purpose: To estimate patient- and episode-level direct costs of chronic obstructive pulmonary 
disease (COPD) among commercially insured patients in the US.
Methods: In this retrospective claims-based analysis, commercial enrollees with evidence of 
COPD were grouped into five mutually exclusive cohorts based on the most intensive level of 
COPD-related care they received in 2006, ie, outpatient, urgent outpatient (outpatient care in addi-
tion to a claim for an oral corticosteroid or antibiotic within seven days), emergency   department 
(ED), standard inpatient admission, and intensive care unit (ICU) cohorts.   Patient-level COPD-
related annual health care costs, including patient- and payer-paid costs, were compared among 
the cohorts. Adjusted episode-level costs were calculated.
Results: Of the 37,089 COPD patients included in the study, 53% were in the outpatient cohort, 
37% were in the urgent outpatient cohort, 3% were in the ED cohort, and the standard admission 
and ICU cohorts together comprised 6%. Mean (standard deviation, SD) annual COPD-related 
health care costs (2008 US$) increased across the cohorts (P , 0.001), ranging from $2003 
($3238) to $43,461 ($76,159) per patient. Medical costs comprised 96% of health care costs 
for the ICU cohort. Adjusted mean (SD) episode-level costs were $305 ($310) for an outpatient 
visit, $274 ($336) for an urgent outpatient visit, $327 ($65) for an ED visit, $9745 ($2968) for 
a standard admission, and $33,440 for an ICU stay.
Conclusion: Direct costs of COPD-related care for commercially insured patients are driven 
by hospital stays with or without ICU care. Exacerbation prevention resulting in reduced need 
for inpatient care could lower costs.
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Introduction
Chronic obstructive pulmonary disease (COPD) is a progressive disease defined by 
an airflow limitation that is not fully reversible.1 Patients with the disease exhibit 
pathologic features of emphysema and, to varying degrees, chronic bronchitis. COPD 
is further typified by periodic worsening of symptoms. Exacerbations, which can be 
life-threatening for certain patients, are characterized by an amplified inflammatory 
response and worsening of airflow. These changes in symptoms are sufficient to war-
rant a change in management and occur an average of approximately three times per 
year for patients with moderate to severe COPD.2 Exacerbations are associated with 
diminished quality of life for COPD patients,3,4 and their frequency and severity, as 
well as the presence of comorbid conditions and the number of medications needed 
to manage the disease, all contribute to COPD severity.1International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
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COPD is highly prevalent in the US5,6 and worldwide.7,8 
The US prevalence6 was estimated at 10 million adults in 
2000, and in 2007, 5.8% of individuals aged 45–64 years 
had physician-diagnosed COPD.5 COPD is a leading cause 
of death in the US, and related mortality has been reported 
to be greater for men than for women, and mortality rates 
are highest for white patients, followed by black, Hispanic, 
and Asian individuals.5
Management of stable COPD is intended to prevent and 
control symptoms and to reduce the frequency and severity 
of exacerbations.1,9,10 Maintenance medications for COPD 
include long- and short-acting bronchodilators, and inhaled 
corticosteroids for patients with repeated exacerbations. 
Fixed-dose combination therapies include short-acting beta 
agonist (SABA)/anticholinergic bronchodilator combina-
tions, and long-acting beta agonist (LABA)/corticosteroid 
combinations.1 Patients with very severe COPD might 
receive oxygen therapy. Medications are generally added as 
the disease progresses.
Exacerbations necessitate intensified management. Res-
cue medication can be started at home, but if the exacerba-
tion is not well managed, hospitalization may be required.1,9 
Patients with severe exacerbations might be managed in the 
emergency department (ED) or hospital, but life-threatening 
exacerbations may require immediate intensive care unit 
(ICU) admission.1 Treatment for exacerbations includes 
increasing the dose or frequency of SABA administration, 
adding an anticholinergic bronchodilator, administering oral 
or intravenous corticosteroids, or oxygen therapy. Because 
exacerbations can be caused by bacterial infection, antibiotics 
might also be given. These events (ED visit, hospitalization) 
and changes in treatment (SABA, oral/intravenous corti-
costeroids, antibiotics) are strongly associated with COPD 
exacerbation and have been used to identify exacerbations 
in clinical research.11–14
The high prevalence and morbidity of COPD contributed 
to a projected $29.5 billion in related direct costs in 2010 in 
the US5 and the annual health care cost was estimated 
at $4119 per COPD patient in 2000.15 Hospitalization 
is a major cost driver in COPD management in various 
health care systems,5,14,16–18 with hospital care projected to 
account for 45% of direct COPD costs in the US in 2010.5 
Prescription drugs comprise approximately 20% of COPD 
costs.5 Disease16 and exacerbation14,17 severity have both been 
identified as COPD cost drivers. However, published data 
appear to be lacking regarding costs for US commercially 
insured patients and US costs according to COPD severity.
Our objective was to estimate direct costs of   COPD-related 
care for commercially insured patients in the US, including 
both health plan- and patient-paid amounts. Specifically, we 
wanted to determine the overall costs generated by patients 
who received care of different intensities, and the costs of 
different types of COPD-related health care visits ranging 
from outpatient visits to ICU stays. We also extrapolated 
the mean annual direct health care cost of COPD for the US 
managed care population.
Material and methods
Data sources
Data for this retrospective analysis were obtained from a 
managed care claims database which included geographi-
cally diverse commercial health plan members in the US. 
The database included data for approximately 14 million 
commercial enrollees during the study period. Enrollment 
information and medical and pharmacy claims from calendar 
year 2006 were used in the analysis. In order to extrapolate 
cost information from the database population to all com-
mercially insured patients in the US, data from the 2006 
Medical Expenditure Panel Survey (MEPS), the most recent 
available, were also used.19 MEPS is a set of nationally rep-
resentative US surveys that collect information on health 
service use, including demographic characteristics and health 
insurance coverage.
Patient selection and cohort formation
Commercially enrolled patients with evidence of COPD from 
January 01, 2006 through December 31, 2006 were included 
in the study population. COPD patients were identified in one 
of the following ways: an ED or inpatient facility claim with 
COPD (ICD-9-CM code 491, 491.0, 491.1, 491.2x, 491.8, 
491.9, 492, 492.0, 492.8, 496) in the primary diagnosis 
position (the diagnosis code must have been on a hospital 
claim for an inpatient stay); an outpatient (routine or urgent 
care) claim with a primary diagnosis of COPD and a second 
medical claim with a COPD diagnosis in any position on a 
separate service date; or a physician claim with a primary or 
secondary diagnosis of COPD and a filled prescription for 
an anticholinergic, LABA, or inhaled corticosteroid/LABA 
combination. Eligible patients were aged 40 years or older 
as of 2006 and were continuously enrolled in the health plan 
with medical and pharmacy benefits during the year-long 
study period. Patients were also required to have race/
ethnicity information available. All data were deidentified and 
accessed with protocols compliant with the Health Insurance International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
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Portability and Accountability Act.20 Privacy board approval 
was obtained for use of race/ethnicity data.
Patient demographic data, including age, gender, and 
geographic region were collected from enrollment informa-
tion. Information on comorbidities, including calculation of 
the Quan–Charlson comorbidity score21 and a flag for asthma 
diagnosis (ICD-9-CM 493.xx), and on fills of respiratory 
medications (based on pharmacy and medical claims) was 
collected to characterize further the patients in the study 
sample.
Patients were grouped into five mutually exclusive 
cohorts based on the most intensive type of COPD-related 
care they had received during the study year. Patients in 
the “outpatient” cohort had at least one medical claim for 
office or outpatient care with COPD indicated in the pri-
mary or secondary position, but no evidence of an urgent 
visit (defined below), ED visit, or inpatient stay for COPD. 
Outpatient care included physician office visits, outpatient 
hospital services, laboratory visits, and urgent care center 
visits. Patients in the “urgent outpatient” cohort had at least 
one medical claim for outpatient care for COPD (primary 
or secondary position) followed by a pharmacy claim for an 
oral corticosteroid or antibiotic within seven days after the 
visit, but no evidence of more serious care. Patients in the 
“ED” cohort had at least one medical claim for an ED visit 
for COPD (primary position) but no evidence of an inpatient 
stay for COPD. The “standard admission” cohort comprised 
patients with at least one inpatient stay for COPD (COPD 
diagnosis in the primary position on a hospital claim), but 
no evidence of ICU treatment during any inpatient stay. 
Patients in the “ICU” cohort had evidence of ICU care 
during a COPD inpatient stay during the study period. ICU 
care was defined as a medical claim during an inpatient 
stay with revenue code of 020x, 021x, 0223 or 0234 or a 
current procedural terminology procedure code for critical 
care (99291–99292). These cohort definitions reflect COPD 
health care encounters associated with regular follow-up and 
exacerbations of increasing severity.1,11,13
For an additional patient-level cost analysis, study 
patients were grouped into cohorts based on race/ethnicity 
as indicated in enrollment information (African American, 
Caucasian, Hispanic, other/unknown).
Cost calculations
Cost calculations were based on total paid amounts in 2006, 
including patient- and health plan-paid amounts, as well as 
estimated Medicare or other payer contributions based on 
coordination of benefits information. To enable comparisons 
with current literature, patient- and episode-level costs, as 
well as costs used in the extrapolation calculation, were 
adjusted to 2008 US dollars using the annual medical care 
component of the Consumer Price Index.22
Patient- and episode-level costs associated with COPD-
related (COPD diagnosis code on a claim associated with 
the visit) outpatient visits, urgent outpatient visits, ED visits, 
standard admissions (no ICU), and ICU stays were identi-
fied. The criteria used to identify these types of visits were 
the same as those used to define the patient cohorts. Costs 
associated with COPD-related care of any intensity that was 
received by each patient, including the cohort-determining 
episode type and less serious visits, were included in the 
analyses. The number of care episodes was counted. For 
ambulatory services, one visit per day per provider was 
allowed.
COPD-related pharmacy costs were summed from phar-
macy claims for any of the following medications: SABAs, 
LABAs, anticholinergics, methylxanthines, oral/intravenous 
corticosteroids, inhaled corticosteroids, inhaled corticoster-
oid/LABA combination, other respiratory medication, or 
antibiotics.
In the patient-level analysis, mean annual total health 
care costs, as well as costs for each type of COPD-related 
visit, other COPD-related medical services (from claims with 
COPD diagnosis in the primary position that did not fall into 
the specified categories), and medications were calculated 
for each of the patient cohorts. Patient-level costs were also 
calculated for race/ethnicity groups.
Costs per COPD-related care episode in 2006 were tabu-
lated based on all episodes of a given type for each cohort 
during the year, and adjusted episode-level costs were esti-
mated using multivariate models. Generalized linear models 
with gamma distribution and log link were used to account 
for the skewed distribution of costs.23 The models of ED and 
inpatient episode-level costs were adjusted for gender, age 
category, geographic region, race/ethnicity, Quan–Charlson 
comorbidity score, and asthma diagnosis. The models of 
episode-level outpatient costs were adjusted for the variables 
listed above, as well as COPD diagnosis code specific to the 
visit, provider type, and season of episode.
A weighted average of total direct annual COPD-related 
costs (medical and pharmacy) for the US managed care 
population was extrapolated, based on cost estimates from the 
sample represented in the study database and demographic 
data from 2006 MEPS.International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
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Statistical analysis
Patient-level cost distributions were compared among cohorts 
using the t-test for continuous variables and the Chi-square 
test for proportions and categoric variables. A P , 0.05 was 
used to define statistical significance. The multivariate mod-
els were fitted by STATA 10.0 (StataCorp, College Station, 
TX) and all other analyses were conducted using SAS 9.1 
(SAS Institute, Cary, NC).
Results
Sample characteristics
Descriptive characteristics of the patient cohorts are shown in 
Table 1. Based on the distribution of patients in the cohorts, 
approximately 90% of eligible COPD patients did not have 
an ED or inpatient visit during the study year. The source 
database population comprises heavily Caucasian indi-
viduals and patients in the South region, and the racial and 
geographic distribution of the database is reflected among 
COPD patients included in the study, as shown in Table 1. 
Most patients in each cohort were aged 50–64 years. Age 
differed significantly among cohorts, with mean age young-
est in the urgent outpatient cohort and oldest in the standard 
admission cohort.
Quan–Charlson comorbidity score differed significantly 
among the care-intensity cohorts, with the lowest mean 
scores in the outpatient cohorts and the highest mean score 
in the ICU cohort (Table 1). Comorbidity scores also dif-
fered significantly by race/ethnicity (P , 0.001), Hispanic 
patients had the lowest mean (standard deviation, SD) score 
at 2.2 (1.8), Caucasian patients had a mean score of 2.3 (1.8), 
and African American patients had the highest mean score 
at 2.5 (2.0).
As expected, the percentage of each cohort that used 
each type of medication during the study year generally 
increased across cohorts (Table 1). Almost half of the 
patients in the study sample received a SABA at some 
point in 2006, with the lowest percentages in the outpatient 
cohorts. Oral/intravenous corticosteroid receipt ranged 
from 30% of patients in the outpatient cohort to 76% of 
patients in the ICU cohort. Oxygen therapy use increased 
across the cohorts, from 14% of the outpatient cohort to 
57% of the ICU cohort. Approximately 35% of patients 
used more than one medication class during the study year 
and 17% of all patients used no maintenance treatment 
(inhaled corticosteroid, LABA, inhaled corticosteroid/
LABA combination, anticholinergic, methylxanthine), but 
did receive rescue medication (ie, SABA, oral/intravenous 
corticosteroid, antibiotic).
Types of visits
Without regard to cohort, the COPD patients included in the 
study had a mean (SD) of 2.7 (2.9) outpatient visits, 0.7 (1.2) 
urgent outpatient visits, 0.08 (0.6) ED visits, and 0.05 (0.3) 
standard admissions during 2006.
The patient cohorts were defined based on the most inten-
sive level of care received, but patients also had visits of less 
serious types. Within each cohort, outpatient visits were the 
most frequently observed type, with the mean count for the 
study year ranging from 2.5 (3.2) for the urgent outpatient 
cohort to 4.6 (4.6) for the ICU cohort (P , 0.001 across 
cohorts). The mean count of standard admissions ranged 
from 0.2 (0.6) for the ICU cohort to 1.1 (0.5) for the standard 
admission cohort (P , 0.001). Among patients who had an 
inpatient stay (ie, patients in the standard admission or ICU 
cohorts), the mean duration of a standard (non-ICU) inpatient 
stay was 10.2 (21.1) days. The ICU cohort averaged 1.1 (0.4) 
ICU visits in 2006, and the mean duration of an ICU stay 
was 1.9 (2.9) days.
Patient-level costs of COPD
As shown in Figure 1, mean (SD) total annual patient-level 
COPD-related costs increased across the cohorts, ranging 
from $2003 ($3238) to $43,461 ($76,159). Medical costs, 
which include costs associated with health care visits, com-
prised the largest portion of COPD-related costs across all 
cohorts. Mean total medical costs increased substantially 
across cohorts (from $1004 per year for the outpatient cohort 
to $41,727 per year for the ICU cohort; P , 0.001 among 
cohorts) but mean pharmacy costs per year changed relatively 
little (from $999 for the outpatient cohort to $1734 for the 
ICU cohort; P , 0.001 among cohorts). Thus, medical costs 
accounted for a progressively greater percentage of total 
COPD-related health care costs; up to 90% for the standard 
admission cohort and 96% for the ICU cohort. All together, 
study patients generated $101,284,860 in COPD-related 
medical costs in 2006 and 34% of that amount was attribut-
able to the ICU cohort. Thus, although patients in the ICU 
cohort comprised 2.2% of the COPD population eligible 
for the study, they accounted for the greatest percentage of 
COPD-related medical costs.
Mean annual patient-level costs of each type of COPD-
related visit are shown in Figure 2. Costs associated with 
each type of visit differed significantly among the applicable 
cohorts (P , 0.001 for all among-cohort comparisons). As 
expected, mean expenditures associated with hospitaliza-
tion and ICU care were substantially greater than costs 
for other types of visits. As shown in Figure 3, mean total Table 1 Characteristics of COPD patients by utilization cohorta
Total 
(n = 37,089)
Outpatient  
cohortb  
(n = 19,641)
Urgent  
outpatient  
cohortc  
(n = 13,833)
ED cohortd  
(n = 1231)
Standard  
admission  
cohorte  
(n = 1547)
ICU cohortf 
(n = 837)
P value
Male, n (%) 18,121 (48.9) 10,149 (51.7) 6300 (45.5) 586 (47.6) 666 (43.1) 420 (50.2) ,0.001
Ethnicity, n (%)
  Caucasian 31,247 (84.3) 16,469 (83.9) 11,742 (84.9) 1023 (83.1) 1312 (84.8) 701 (83.8) 0.081
  African American 1958 (5.3) 1054 (5.4) 650 (4.7) 86 (7.0) 109 (7.1) 59 (7.1) ,0.001
  Hispanic 1249 (3.4) 679 (3.5) 476 (3.4) 45 (3.7) 31 (2.0) 18 (2.2) 0.008
  Other/unknown 2635 (7.1) 1439 (7.3) 965 (7.0) 77 (6.3) 95 (6.1) 59 (7.1) 0.254
Region, n (%)
  Northeast 4155 (11.2) 2419 (12.3) 1355 (9.8) 107 (8.7) 197 (12.7) 77 (9.2) ,0.001
  Midwest 9988 (26.9) 5251 (26.7) 3664 (26.5) 391 (31.8) 461 (29.8) 221 (26.4) ,0.001
  South 16,807 (45.3) 8537 (43.5) 6630 (47.9) 566 (46.0) 684 (44.2) 390 (46.6) ,0.001
  West 6139 (16.6) 3434 (17.5) 2184 (15.8) 167 (13.6) 205 (13.3) 149 (17.8) ,0.001
Age, n (%)
  40–49 4449 (12.0) 2262 (11.5) 1900 (13.7) 132 (10.7) 105 (6.8) 50 (6.0) ,0.001
  50–64 18,545 (50.0) 9645 (49.1) 7239 (52.3) 621 (50.5) 656 (42.4) 384 (45.9) ,0.001
  65–74 7225 (19.5) 3925 (20.0) 2572 (18.6) 233 (18.9) 304 (19.7) 191 (22.8) 0.003
 $ 75 6870 (18.5) 3809 (19.4) 2122 (15.3) 245 (19.9) 482 (31.2) 212 (25.3) ,0.001
Asthma  
diagnosis, n (%)
12,150 (32.8) 5620 (28.6) 5059 (36.6) 545 (44.3) 602 (38.9) 324 (38.7) ,0.001
Quan–Charlson 
score, mean (SD)
2.3 (1.8) 2.3 (1.7) 2.3 (1.8) 2.7 (2.1) 3.1 (2.2) 3.8 (2.4) ,0.001
Medicationg, n (%)
  SABA 17,486 (47.2) 7490 (38.1) 7668 (55.4) 811 (65.9) 996 (64.4) 521 (62.3) ,0.001
  LABA 2039 (5.5) 979 (5.0) 816 (5.9) 72 (5.9) 110 (7.1) 62 (7.4) ,0.001
  Anticholinergics 19,650 (53.0) 9435 (48.0) 7810 (56.5) 755 (61.3) 1047 (67.7) 603 (72.0) ,0.001
  Methylxanthines 2000 (5.4) 782 (4.0) 843 (6.1) 120 (9.8) 155 (10.0) 100 (12.0) ,0.001
    Oral/IV  
corticosteroids
18,251 (49.2) 5889 (30.0) 9676 (69.9) 930 (75.5) 1123 (72.6) 633 (75.6) ,0.001
  ICS 4601 (12.4) 2033 (10.4) 1994 (14.4) 193 (15.7) 241 (15.6) 140 (16.7) ,0.001
    ICS + LABA 
combination
15,736 (42.4) 7838 (39.9) 6359 (46.0) 513 (41.7) 641 (41.4) 385 (46.0) ,0.001
    Other respiratory 
medications
6042 (16.3) 2671 (13.6) 2696 (19.5) 263 (21.4) 256 (16.5) 156 (18.6) ,0.001
  Oxygen therapy 6986 (18.8) 2834 (14.4) 2522 (18.2) 408 (33.1) 742 (48.0) 480 (57.3) ,0.001
  Antibiotics 27,230 (73.4) 11,162 (56.8) 13,043 (94.3) 1045 (84.9) 1287 (83.2) 693 (82.8) ,0.001
    Nonrespiratory 
medications
34,859 (94.0) 18,039 (91.8) 13,473 (97.4) 1142 (92.8) 1419 (91.7) 786 (93.9) ,0.001
Notes: aPatients were grouped into five mutually exclusive cohorts based on the most intensive type of COPD-related care they received; bCohort comprising patients with 
at least one medical claim for outpatient care and no more intensive care; cCohort comprising patients with at least one medical claim for outpatient care for COPD followed 
by a pharmacy claim for an oral corticosteroid or antibiotic within seven days and no more intensive care; dCohort comprising patients with at least one medical claim for an 
ED visit for COPD and no more intensive care; eCohort comprising patients with at least one inpatient stay for COPD and no ICU care; fCohort comprising patients with 
evidence of ICU care during an inpatient stay; gAt least one fill during the observation period.
Abbreviations: ED, emergency department; ICS, inhaled corticosteroid; ICU, intensive care unit; IV, intravenous; LABA, long-acting beta agonist; SABA, short-acting beta 
agonist; SD, standard deviation, COPD, chronic obstructive pulmonary disease.
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  COPD-related health care costs were approximately 21% to 
25% lower for Hispanic patients than for patients of other 
races (among-group P = 0.135).
Episode-level costs of COPD
The adjusted mean costs of a health care episode of each 
type are shown in Figure 4. Episode costs increased for 
more   serious types of visits, with the most notable difference 
between outpatient/ED visits and inpatient/ICU visits. The 
adjusted mean cost of a COPD-related standard admission 
among all patients who had one was $9745, and an ICU stay 
increased the cost to $33,440 per episode.
Population-level cost of COPD
Based on MEPS data and data from this study, the 2006 
prevalence of COPD among commercially insured patients International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
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in the US was estimated at 2.9 million. This population was 
predicted to generate $15.7 billion (in 2008 US$) in annual 
direct health care costs, comprising approximately $12.4 bil-
lion in medical costs and $3.3 billion in COPD-related 
pharmacy costs.
Discussion
Our study provides estimated episode-level COPD-related 
encounter costs, including costs of an outpatient visit, ED 
visit, standard hospitalization and hospital admission result-
ing in an ICU stay, as well as patient-level direct annual 
COPD-related health care costs. The results show that costs 
increase according to the intensity of care received and 
expand on previous studies with the inclusion of commer-
cial managed care patients, outpatient encounters, and costs 
stratified according to resource use suggestive of a range of 
COPD severities.
Stanford et al24 and Dalal et al25 provided hospital-
perspective episode-level costs of encounters for a national 
sample of COPD patients for 2001 and 2005 through 2008. 
These previous studies reported that ICU visits, and intu-
bation specifically, accounted for a small proportion of 
  COPD-related encounters, but a high proportion of costs. 
Costs associated with an ICU stay were approximately triple 
the costs of a standard admission for their national samples 
of patients with various health care payers, as well as for the 
commercial managed care patients in our study. Consistent 
with their hospital-perspective observations,24,25 we found 
that the ICU cohort generated a disproportionate share of 
health care costs from the perspective of patients and health 
plan payers. The cost of an ICU episode was much higher 
than costs for other types of visits, and mean annual health 
care costs were also substantially greater for patients who 
had an ICU encounter. These studies suggest that minimizing 
the need for hospitalization, and the ICU in particular, could 
lower COPD-related health care costs.
As guidelines advocate1 and observational studies bear 
out,2,14 COPD exacerbations can necessitate intensified 
medical resource use. Our findings are consistent with 
reports indicating that escalated use of medical resources 
drives COPD-associated health care costs.5,14–18 Our results 
further suggest that care indicative of more severe exac-
erbations (ie, hospitalization and ICU care) is associated 
with higher episode- and patient-level costs for patients 
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Figure 1 Mean annual COPD-related medical, pharmacy, and total costs by care intensity cohort. P , 0.001 among cohorts for medical costs, P , 0.001 among cohorts for 
pharmacy costs, and P , 0.001 among cohorts for total COPD-related costs. 
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in the US. A   Canadian study of COPD-related health care 
encounters also determined that severe exacerbations requir-
ing hospitalization were associated with substantially higher 
episode-level costs than moderate-severity exacerbations, 
defined according to treatment in an outpatient or ED 
setting.14 Disease management initiatives targeted to prevent-
ing exacerbations may reduce health care costs by minimizing 
COPD-related need for inpatient resources.26 In addition, pre-
vious research suggests that reducing exacerbation   frequency 
may improve patient quality of life.3
The results presented here must be interpreted in the 
context of certain limitations. As for all claims-based stud-
ies, it should be noted that claims are collected for payment, 
not research, and the analysis is constrained by the codes 
and other information contained in claims. If, for example, 
a critical care code was present on a claim for care that did 
not actually occur in the ICU, then ICU episodes might be 
overestimated based on our criteria. However, we believe 
that such cases are rare, and that the codes used to identify 
episode types provide a reasonable estimate of the range of 
care received by COPD patients. Claims data provide limited 
detail regarding in-hospital medication use. Because oxygen 
is often administered in the inpatient setting, this could 
account for the unexpectedly low proportion of patients in 
the ICU cohort that had evidence of oxygen use. The data 
limit our cost analysis to direct costs, but because indirect 
costs of COPD are also substantial,5,15,27 the health care costs 
presented here underestimate the overall burden of COPD. 
In addition, clinical measures of COPD severity, such as 
spirometry, were not available in the claims data to validate 
the cohort classification based on the level of care the patients 
received. With regard to the analyses by race, differences in 
health status and treatment patterns, as well as differences in 
care-seeking behavior, could affect the reported observations. 
The causal contributions of these factors cannot be discerned 
from this study. Claims data enabled us to focus on com-
mercial managed care patients, but our findings might not 
generalize to patients with other types of health care plans, 
most notably Medicare. Finally, the extrapolation method 
assumes that the distribution of COPD diagnoses and costs 
of the population in the research database are similar to the 
US managed care population.
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COPD costs in managed care patients
Conclusion
COPD imposes a substantial direct cost burden on patients 
and commercial payers. Total direct health care costs are 
driven by medical costs, and COPD-related medical resource 
use may be considered a proxy for exacerbations. Patients 
with care indicative of more severe exacerbations had both 
higher episode- and patient-level costs. These findings sug-
gest that improved symptom management and reduction in 
exacerbations would reduce the need for escalated care and 
subsequently reduce overall costs.
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